# SystImmune Inc.: Phase 3 study in Urothelial Cancer, Metastatic Urothelial Cancer (520 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | SystImmune Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy |
| NCT ID | NCT07869836 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Urothelial Cancer; Metastatic Urothelial Cancer; Bladder Cancer; Bladder Cancer (BC); Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable |
| Intervention types | drug |
| Target enrollment | 520 |
| Site countries | United States |
| Posted | 2026-10-13 |
| Planned start | 2026-09 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 520 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07869836). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.